Lindsay Lohan can't help it that she's popular. The 32-year-old actress, who lives overseas, joined a slew of celebs at the annual MTV Europe Music Awards in Bilbao, Spain on...
Reported by E! Online 1 hour ago.
Lindsay Lohan Glitters in Gold on 2018 MTV EMAs Red Carpet
↧
↧
Dua Lipa & Alessia Step Out for MTV EMAs 2018
Dua Lipa arrives in style for the 2018 MTV EMAs held at the Bilbao Exhibition Centre on Sunday (November 4) in Bilbao, Spain. Also seen walking the red carpet that day for the music awards show was Alessia Cara. This year, Dua Lipa is up for multiple nominations including Best Artist, Best Pop, and Best [...]
Reported by Just Jared 1 hour ago.
↧
Jason Derulo & Sofia Reyes Step Out at MTV EMAs 2018!
Jason Derulo and Sofia Reyes teamed up while hitting the carpet at the 2018 MTV EMAs! The duo, who collabed on Sofia‘s song “1, 2, 3,” stepped out at the award ceremony on Sunday (November 4) at the Bilbao Exhibition Centre in Bilbao, Spain. Before they walked the carpet, Sofia performed the song during the [...]
Reported by Just Jared 1 hour ago.
↧
Sofia Reyes Reunites With Jason Derulo at MTV EMAs 2018!
Sofia Reyes and Jason Derulo reunited at the 2018 MTV EMAs! The duo, who worked on Sofia‘s song “1, 2, 3″ together, hit the red carpet on Sunday (November 4) at the Bilbao Exhibition Centre in Bilbao, Spain. Before they walked the carpet, Sofia performed the song during the event’s pre-show. Jason will perform his [...]
Reported by Just Jared Jr 11 minutes ago.
↧
Sevilla fall further behind leaders Barca with draw at Sociedad
SAN SEBASTIAN, Spain (Reuters) - Sevilla failed to capitalise on a weekend of slip-ups for La Liga's chasing pack when they were held to a goalless draw away to Real Sociedad on Sunday, opening up a four-point gap behind leaders and champions Barcelona.
Reported by SBS 37 minutes ago.
↧
↧
Brendon Urie, Marshmello, & More Performers Arrive at MTV EMAs 2018
Brendon Urie lets out a smile on the red carpet at the 2018 MTV EMAs held at the Bilbao Exhibition Centre on Sunday (November 4) in Bilbao, Spain. The Panic! At The Disco lead singer was joined at the event by fellow performers Marshmello, with Bastille, and David Guetta. Panic! At The Disco will be [...]
Reported by Just Jared 26 minutes ago.
↧
Brendan Urie, Marshemello, & More Performers Arrive at MTV EMAs 2018
Brendan Urie lets out a smile on the red carpet at the 2018 MTV EMAs held at the Bilbao Exhibition Centre on Sunday (November 4) in Bilbao, Spain. The Panic! At The Disco lead singer was joined at the event by fellow performers Marshmello, with Bastille, and David Guetta. Panic! At The Disco will be [...]
Reported by Just Jared 48 minutes ago.
↧
Dua Lipa stuns in thigh-grazing floral playsuit as she heads into MTV EMAs in Spain
Dua Lipa dazzled as she arrived at the Bilbao Exhibition Centre in Bilbao, Spain for the MTV EMA awards.
Reported by MailOnline 15 minutes ago.
↧
Nicki Minaj Performs at MTV EMAs 2018!
Nicki Minaj is so fierce while taking the stage at the 2018 MTV EMAs held at the Bilbao Exhibition Centre on Sunday (November 4) in Bilbao, Spain. First, the 35-year-old rapper performed “Good Form” before welcoming Little Mix on stage. They then performed “Woman Like Me” together at the music awards show. PHOTOS: Check out [...]
Reported by Just Jared 26 minutes ago.
↧
↧
Jack & Jack Join Anne-Marie on MTV EMAs 2018 Pink Carpet!
Jack & Jack suited up while hitting the carpet at the 2018 MTV EMAs! The duo – Jack Johnson and Jack Gilinsky – stepped out at the event on Sunday (November 4) at the Bilbao Exhibition Centre in Bilbao, Spain. They were joined at the award ceremony by Anne-Marie and Debby Ryan. During the show, [...]
Reported by Just Jared 5 minutes ago.
↧
MTV EMAs 2018 - Performers & Presenters List Revealed!
The 2018 MTV EMAs are set to air tonight on MTV and we have the full list of celebs you can expect to be in attendance! Because the show took place live from Bilbao, Spain, the broadcast on MTV will be airing a few hours after the event ends. You can check out Just Jared‘s [...]
Reported by Just Jared 5 minutes ago.
↧
Global RFID In Healthcare Market to be worth USD 5.2 Billion By 2024: Zion Market Research
RFID in Healthcare Market – by Components (Readers, Tags, Printers, and Cabinets), by Application (Supply Chain and Medical Report, Samples and Blood Transfer Tracking, People Identification and Tracking, Medicine Tracking, and Equipment Tracking), and by End User (Hospitals, Biotechnology Companies, and Pharmaceutical Companies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024
New York, NY, Nov. 05, 2018 (GLOBE NEWSWIRE) -- According to the report, global demand for RFID in healthcare market was valued at approximately USD 1.3 billion in 2017, and is expected to generate revenue of around USD 5.2 billion by end of 2024, growing at a CAGR of around 21.54% between 2018 and 2024.
Radiofrequency identification (RFID) is a wireless technology that uses radio waves to collect information from a tag that is attached to an article for a variety of purposes. RFID is most frequently used to track objects and their automatic identification. Logistics and supply chain, government, and retail are the main application areas of RFID. The use of RFID technology in the healthcare sector has seen an upward trend in the recent past. The applications of RFID in healthcare market include supply chain and medical report, samples and blood transfer tracking, people identification and tracking, medicine tracking, and equipment tracking. The end user of RFID in Healthcare Market are hospitals, biotechnology companies, and pharmaceutical companies among others. RFID technology helps in enhancing inventory management in pharmacies, hospitals, and biotechnology industries. It also enables healthcare providers to advance patient safety. The deployment of RFID systems in hospitals can enhance patient flow, regulate implants & inventories, enhance the utilization rate of assets, and lessen medical faults.
*Get a Sample of this Research Report:* https://www.zionmarketresearch.com/sample/rfid-in-healthcare-market
Factors such as inventory management enhancement in pharmacies, hospitals, and biotech companies, high accuracy and low-cost of RFID systems, growing automation of processes in pharmacies and hospitals, increasing concern regarding drug safety, rising need for reduction of healthcare operational costs, need for prevention of medical device theft, multiple government initiatives, and wide application range of RFID in healthcare will act as the driving factors for the growth of global RFID in healthcare market. Research activities undertaken by not for profit organizations intended for the development of new and improved technologies and increasing adoption of RFID in healthcare will act as an opportunity for the market players in the RFID in healthcare market. However, the absence of awareness regarding RFID, lack of barcode systems, and absence of standardization will restrict the growth of global RFID in the healthcare market.
The global RFID in healthcare market has been segmented into components, application, end user, and region. The components segment has been divided into readers, tags, printers, and cabinets. Tags sub-segment holds the majority share in the components segment due to its high penetration across myriad sectors. Based on application, RFID in healthcare market has been segmented into supply chain and medical report, samples and blood transfer tracking, people identification and tracking, medicine tracking, and equipment tracking. Samples and blood transfer tracking sub-segment holds the majority share of the application segment due to growing requirement of blood products inventory management. Based on end user, RFID in healthcare market has been segmented into hospitals, biotechnology companies, and pharmaceutical companies. North America represents the established regional market for RFID in healthcare and will show fast growth in the near future. The U.S. is the leading RFID in healthcare market by country in North America. The U.S. will advance at topmost CAGR during the anticipated timeframe. This growth can be attributed to increasing collaborations in medical device industry, intensive research and developments activities conducted by not for profit organizations, and the presence of advanced healthcare infrastructure. Moreover, rise in government funding on healthcare is likely to motivate the growth of RFID in healthcare market.
*Download PDF Report Brochure for more Insights:* https://www.zionmarketresearch.com/requestbrochure/rfid-in-healthcare-market
Europe will display a remarkable growth in the near future. The growth is majorly due to high operational efficiency in healthcare, initiatives taken by the governments, and increasing demand for reduction in costs.
The Asia Pacific region is expected to progress at the paramount rate during the estimated period. Japan, India, and China are expected to take forward the growth for RFID in the healthcare market. Development in Asia Pacific is expected to be driven by the availability of services like original equipment manufacturing (OEM) in China at cost-effective rates and increasing adoption of RFID systems.
The Middle East & Africa region is anticipated to demonstrate restricted growth due to dearth of government spending, and absence of latest infrastructure. Latin America will record noticeable growth over the estimated period due to rise in government initiatives, and growing awareness about RFID and its applications.
*Request Customized copy of report @ *https://www.zionmarketresearch.com/custom/270
This report segments the global RFID in healthcare market as follows:
*Global RFID in Healthcare Market: By Components*
· Readers
· Tags
· Printers
· Cabinets
*Global RFID in Healthcare Market: By Application*
· Supply Chain and Medical Report
· Samples and Blood Transfer Tracking
· People Identification and Tracking
· Medicine Tracking
· Equipment Tracking
*Global RFID in Healthcare Market: By End User*
· Hospitals
· Biotechnology Companies
· Pharmaceutical Companies
*Global **RFID in Healthcare Market: By Region*
· North America
· U.S.
· Canada
· Rest of North America
· Europe
· Germany
· UK
· France
· Italy
· Spain
· Russia
· Rest of Europe
· Asia Pacific
· China
· Japan
· India
· Australia
· Rest of Asia Pacific
· Latin America
· Brazil
· Mexico
· Argentina
· Rest of Latin America
· The Middle East and Africa
· Saudi Arabia
· UAE
· South Africa
· Qatar
· Rest of the Middle East and Africa
*About Us:*
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
*Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
*Follow Us Twitter: *https://twitter.com/zion_research
*Blog:* http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com
*Contact Us:*
Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
*Website:* https://www.zionmarketresearch.com
*Blog: *http://zmrblog.com Reported by GlobeNewswire 10 hours ago.
New York, NY, Nov. 05, 2018 (GLOBE NEWSWIRE) -- According to the report, global demand for RFID in healthcare market was valued at approximately USD 1.3 billion in 2017, and is expected to generate revenue of around USD 5.2 billion by end of 2024, growing at a CAGR of around 21.54% between 2018 and 2024.
Radiofrequency identification (RFID) is a wireless technology that uses radio waves to collect information from a tag that is attached to an article for a variety of purposes. RFID is most frequently used to track objects and their automatic identification. Logistics and supply chain, government, and retail are the main application areas of RFID. The use of RFID technology in the healthcare sector has seen an upward trend in the recent past. The applications of RFID in healthcare market include supply chain and medical report, samples and blood transfer tracking, people identification and tracking, medicine tracking, and equipment tracking. The end user of RFID in Healthcare Market are hospitals, biotechnology companies, and pharmaceutical companies among others. RFID technology helps in enhancing inventory management in pharmacies, hospitals, and biotechnology industries. It also enables healthcare providers to advance patient safety. The deployment of RFID systems in hospitals can enhance patient flow, regulate implants & inventories, enhance the utilization rate of assets, and lessen medical faults.
*Get a Sample of this Research Report:* https://www.zionmarketresearch.com/sample/rfid-in-healthcare-market
Factors such as inventory management enhancement in pharmacies, hospitals, and biotech companies, high accuracy and low-cost of RFID systems, growing automation of processes in pharmacies and hospitals, increasing concern regarding drug safety, rising need for reduction of healthcare operational costs, need for prevention of medical device theft, multiple government initiatives, and wide application range of RFID in healthcare will act as the driving factors for the growth of global RFID in healthcare market. Research activities undertaken by not for profit organizations intended for the development of new and improved technologies and increasing adoption of RFID in healthcare will act as an opportunity for the market players in the RFID in healthcare market. However, the absence of awareness regarding RFID, lack of barcode systems, and absence of standardization will restrict the growth of global RFID in the healthcare market.
The global RFID in healthcare market has been segmented into components, application, end user, and region. The components segment has been divided into readers, tags, printers, and cabinets. Tags sub-segment holds the majority share in the components segment due to its high penetration across myriad sectors. Based on application, RFID in healthcare market has been segmented into supply chain and medical report, samples and blood transfer tracking, people identification and tracking, medicine tracking, and equipment tracking. Samples and blood transfer tracking sub-segment holds the majority share of the application segment due to growing requirement of blood products inventory management. Based on end user, RFID in healthcare market has been segmented into hospitals, biotechnology companies, and pharmaceutical companies. North America represents the established regional market for RFID in healthcare and will show fast growth in the near future. The U.S. is the leading RFID in healthcare market by country in North America. The U.S. will advance at topmost CAGR during the anticipated timeframe. This growth can be attributed to increasing collaborations in medical device industry, intensive research and developments activities conducted by not for profit organizations, and the presence of advanced healthcare infrastructure. Moreover, rise in government funding on healthcare is likely to motivate the growth of RFID in healthcare market.
*Download PDF Report Brochure for more Insights:* https://www.zionmarketresearch.com/requestbrochure/rfid-in-healthcare-market
Europe will display a remarkable growth in the near future. The growth is majorly due to high operational efficiency in healthcare, initiatives taken by the governments, and increasing demand for reduction in costs.
The Asia Pacific region is expected to progress at the paramount rate during the estimated period. Japan, India, and China are expected to take forward the growth for RFID in the healthcare market. Development in Asia Pacific is expected to be driven by the availability of services like original equipment manufacturing (OEM) in China at cost-effective rates and increasing adoption of RFID systems.
The Middle East & Africa region is anticipated to demonstrate restricted growth due to dearth of government spending, and absence of latest infrastructure. Latin America will record noticeable growth over the estimated period due to rise in government initiatives, and growing awareness about RFID and its applications.
*Request Customized copy of report @ *https://www.zionmarketresearch.com/custom/270
This report segments the global RFID in healthcare market as follows:
*Global RFID in Healthcare Market: By Components*
· Readers
· Tags
· Printers
· Cabinets
*Global RFID in Healthcare Market: By Application*
· Supply Chain and Medical Report
· Samples and Blood Transfer Tracking
· People Identification and Tracking
· Medicine Tracking
· Equipment Tracking
*Global RFID in Healthcare Market: By End User*
· Hospitals
· Biotechnology Companies
· Pharmaceutical Companies
*Global **RFID in Healthcare Market: By Region*
· North America
· U.S.
· Canada
· Rest of North America
· Europe
· Germany
· UK
· France
· Italy
· Spain
· Russia
· Rest of Europe
· Asia Pacific
· China
· Japan
· India
· Australia
· Rest of Asia Pacific
· Latin America
· Brazil
· Mexico
· Argentina
· Rest of Latin America
· The Middle East and Africa
· Saudi Arabia
· UAE
· South Africa
· Qatar
· Rest of the Middle East and Africa
*About Us:*
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
*Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
*Follow Us Twitter: *https://twitter.com/zion_research
*Blog:* http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com
*Contact Us:*
Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
*Website:* https://www.zionmarketresearch.com
*Blog: *http://zmrblog.com Reported by GlobeNewswire 10 hours ago.
↧
Camila Cabello dominates the 2018 MTV EMAs, wins best artist and song
Cabello was the big winner at the MTV EMAs gala in Spain on Sunday, while Janet Jackson took a stand for women's rights.
Reported by USATODAY.com 9 hours ago.
Reported by USATODAY.com 9 hours ago.
↧
↧
Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas
– AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC –– Full enrollment expected in two years with response rate as primary endpoint –
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the initiation of its global, multi-center, registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC).
“We are excited to announce that our first registration-directed trial is now underway,” said Antonio Gualberto, M.D., Ph.D., Head of Development and Chief Medical Officer of Kura Oncology. “Prior to our experience, tipifarnib was studied in more than 5,000 patients and although it demonstrated compelling anti-cancer activity in some cases, no molecular target was identified that could explain such activity. This registration-directed trial implements the many learnings from our clinical experience in patients with HNSCC. We believe we can now identify those patients most likely to receive clinical benefit from tipifarnib. If successful, we believe this registration-directed trial could bring a much-needed treatment option to patients with HRAS mutant HNSCC.”
*About the Registration-Directed Trial*
Kura’s registration-directed clinical trial is a global, multi-center study of tipifarnib in HRAS mutant HNSCC. The open-label trial has two cohorts: AIM-HN, a treatment cohort, and SEQ-HN, a non-interventional screening and outcomes cohort.
AIM-HN is designed to enroll at least 59 patients with HRAS mutant HNSCC who have received prior platinum-based therapy, and is expected to take approximately two years to fully enroll. Based on observations from Kura’s Phase 2 trial, patients in AIM-HN must have a tumor HRAS mutant allele frequency of at least 20%. Enrolled patients will receive a starting dose of 600 mg of oral tipifarnib, twice daily, on days 1-7 and 15-21 of 28-day treatment cycles. The trial’s primary endpoint is objective response rate (ORR), as determined by independent radiological review. Secondary outcome measures will include overall survival, duration of response, progression free survival and time to response.
AIM-HN has approximately 80% power to detect a difference between a null hypothesis of 15%, which is the point estimate of the ORR of second-line therapy for recurrent and metastatic disease, and 30%, an ORR considered of interest. Based on feedback from the U.S. Food and Drug Administration (FDA), Kura believes that AIM-HN, if positive, may be adequate to support a new drug application (NDA) seeking accelerated approval.
SEQ-HN is an observational cohort and is designed as a case-control study, matching patients with recurrent or metastatic HNSCC with HRAS mutations against those who are HRAS wild type using factors such as age, line of therapy and type of treatment. SEQ-HN is expected to provide a better understanding of the natural history of patients with HRAS mutations while contributing to identify patients for potential enrollment into AIM-HN. HNSCC patients in whom HRAS mutations are identified and who meet eligibility criteria will be offered participation in AIM-HN. HNSCC patients in whom HRAS mutations are not identified may enroll into SEQ-HN.
Additional information about the trial can be found at clinicaltrials.gov using the identifier NCT03719690.
*About Tipifarnib*
Kura Oncology’s lead candidate, tipifarnib, is an inhibitor of farnesylation, a key cell signaling process implicated in cancer initiation and development. In extensive clinical trials, tipifarnib has shown compelling and durable anti-cancer activity in certain patient subsets. Leveraging advances in next-generation sequencing as well as emerging information about cancer genetics and tumor biology, the Company is seeking to identify those patients most likely to benefit from tipifarnib. In addition to its development program in solid tumors with HRAS mutations, Kura has identified the CXCL12 pathway and bone marrow homing of myeloid cells as potential biomarkers of activity for tipifarnib in certain hematologic malignancies. The Company plans to present preliminary data from the angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ expansion cohorts in a Phase 2 trial of tipifarnib in peripheral T-cell lymphomas (PTCL) at the American Society of Hematology Annual Meeting in December 2018.
*About Kura Oncology*
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, for which the Company has initiated a registration-directed trial of tipifarnib in at least 59 recurrent or metastatic patients with HRAS mutant head and neck squamous cell carcinomas. In addition, tipifarnib is being evaluated in multiple other Phase 2 clinical trials in solid tumor and hematologic indications. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in IND-enabling studies. For additional information about Kura Oncology, please visit the Company’s website at www.kuraoncology.com.
*Forward-Looking Statements*
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of tipifarnib, the conduct, results and timing of Kura Oncology’s clinical trials including the Phase 2 HRAS mutant HNSCC and SCC trial and AIM-HN trial, the timing of release of clinical trial results, plans regarding future clinical trials and development activities and the regulatory approval path for tipifarnib. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura Oncology may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipated,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura Oncology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
*Contacts*
Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com
Investors:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com Reported by GlobeNewswire 9 hours ago.
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the initiation of its global, multi-center, registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC).
“We are excited to announce that our first registration-directed trial is now underway,” said Antonio Gualberto, M.D., Ph.D., Head of Development and Chief Medical Officer of Kura Oncology. “Prior to our experience, tipifarnib was studied in more than 5,000 patients and although it demonstrated compelling anti-cancer activity in some cases, no molecular target was identified that could explain such activity. This registration-directed trial implements the many learnings from our clinical experience in patients with HNSCC. We believe we can now identify those patients most likely to receive clinical benefit from tipifarnib. If successful, we believe this registration-directed trial could bring a much-needed treatment option to patients with HRAS mutant HNSCC.”
*About the Registration-Directed Trial*
Kura’s registration-directed clinical trial is a global, multi-center study of tipifarnib in HRAS mutant HNSCC. The open-label trial has two cohorts: AIM-HN, a treatment cohort, and SEQ-HN, a non-interventional screening and outcomes cohort.
AIM-HN is designed to enroll at least 59 patients with HRAS mutant HNSCC who have received prior platinum-based therapy, and is expected to take approximately two years to fully enroll. Based on observations from Kura’s Phase 2 trial, patients in AIM-HN must have a tumor HRAS mutant allele frequency of at least 20%. Enrolled patients will receive a starting dose of 600 mg of oral tipifarnib, twice daily, on days 1-7 and 15-21 of 28-day treatment cycles. The trial’s primary endpoint is objective response rate (ORR), as determined by independent radiological review. Secondary outcome measures will include overall survival, duration of response, progression free survival and time to response.
AIM-HN has approximately 80% power to detect a difference between a null hypothesis of 15%, which is the point estimate of the ORR of second-line therapy for recurrent and metastatic disease, and 30%, an ORR considered of interest. Based on feedback from the U.S. Food and Drug Administration (FDA), Kura believes that AIM-HN, if positive, may be adequate to support a new drug application (NDA) seeking accelerated approval.
SEQ-HN is an observational cohort and is designed as a case-control study, matching patients with recurrent or metastatic HNSCC with HRAS mutations against those who are HRAS wild type using factors such as age, line of therapy and type of treatment. SEQ-HN is expected to provide a better understanding of the natural history of patients with HRAS mutations while contributing to identify patients for potential enrollment into AIM-HN. HNSCC patients in whom HRAS mutations are identified and who meet eligibility criteria will be offered participation in AIM-HN. HNSCC patients in whom HRAS mutations are not identified may enroll into SEQ-HN.
Additional information about the trial can be found at clinicaltrials.gov using the identifier NCT03719690.
*About Tipifarnib*
Kura Oncology’s lead candidate, tipifarnib, is an inhibitor of farnesylation, a key cell signaling process implicated in cancer initiation and development. In extensive clinical trials, tipifarnib has shown compelling and durable anti-cancer activity in certain patient subsets. Leveraging advances in next-generation sequencing as well as emerging information about cancer genetics and tumor biology, the Company is seeking to identify those patients most likely to benefit from tipifarnib. In addition to its development program in solid tumors with HRAS mutations, Kura has identified the CXCL12 pathway and bone marrow homing of myeloid cells as potential biomarkers of activity for tipifarnib in certain hematologic malignancies. The Company plans to present preliminary data from the angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ expansion cohorts in a Phase 2 trial of tipifarnib in peripheral T-cell lymphomas (PTCL) at the American Society of Hematology Annual Meeting in December 2018.
*About Kura Oncology*
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, for which the Company has initiated a registration-directed trial of tipifarnib in at least 59 recurrent or metastatic patients with HRAS mutant head and neck squamous cell carcinomas. In addition, tipifarnib is being evaluated in multiple other Phase 2 clinical trials in solid tumor and hematologic indications. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in IND-enabling studies. For additional information about Kura Oncology, please visit the Company’s website at www.kuraoncology.com.
*Forward-Looking Statements*
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of tipifarnib, the conduct, results and timing of Kura Oncology’s clinical trials including the Phase 2 HRAS mutant HNSCC and SCC trial and AIM-HN trial, the timing of release of clinical trial results, plans regarding future clinical trials and development activities and the regulatory approval path for tipifarnib. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura Oncology may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipated,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura Oncology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
*Contacts*
Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com
Investors:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com Reported by GlobeNewswire 9 hours ago.
↧
Perrie Edwards says she's at a loss for words over 'putting my face on Nicki Minaj's a**e'
The Woman Like Me hitmaker, 25, revealed she was overwhelmed with delight over her energetic performance with her bandmates and Nicki Minaj at the Bilbao Exhibition Centre in Bilbao, Spain.
Reported by MailOnline 9 hours ago.
↧
Camila Cabello wins best artist and best song at MTV EMAs
Camila Cabello was the big winner at the MTV EMAs gala in Spain on Sunday, while Janet Jackson used her acceptance speech for a life-time achievement award to take a stand for women's rights. (Nov. 5)
Reported by USATODAY.com 8 hours ago.
Reported by USATODAY.com 8 hours ago.
↧
Janet Jackson Rallies Her "Sisters" With Empowering Feminist Speech
There's a reason Janet Jackson received the Global Icon Award last night. Taking the stage in Bilbao, Spain, for the MTV European Music Awards, the 52-year-old entertainer used her...
Reported by E! Online 7 hours ago.
↧
↧
Real Madrid's Dani Carvajal defends sacked coach Julen Lopetegui
Real Madrid defender Dani Carvajal says sacked coach Julen Lopetegui is the best manager he has worked under.
Lopetegui was dismissed last week after less than five months in charge of Real, following a hefty Clasico defeat by Barcelona and a dire run of form in which they sunk to ninth in La Liga.
The coach has endured a nightmare year after being sacked by Spain on the eve of the World Cup after agreeing to take the Real Madrid job.
However, Carvajal, who won three Champions League titles with Real under Zinedine Zidane, is standing by Lopetegui.
"For me, he's the best coach that I have had," Carvajal told TVE. "Unfortunately, he lacked the bit of luck necessary to continue with us. His way of seeing football, his way of managing the group, of being with the players, is something I share.
"I said it before he arrived at Real Madrid, I'm still saying it now he´s gone, and I will keep saying it until I have a coach that's better than him."
Lopetegui's replacement, interim coach Santiago Solari, has two wins from his two matches in charge, although Carvajal has not featured due to a calf injury.
The right back is not available for Real's trip to the Czech Republic to face Viktoria Plzen in the Champions League on Wednesday.
Article Type:
Report
Sections:
Sports
Agencies:
Reuters
Tags:
Real Madrid
Dani Carvajal
Julen Lopetegui
Football
Barcelona
La Liga
Santiago Solari
Zinedine Zidane
Madrid
Spain
Mon, 5 Nov 2018-07:58pm
Date updated:
Monday, 5 November 2018 - 7:58pm
Article Images:
Reuters
Short URL:
dnai.in/fKzq
Embargo:
Syndicate:
Hide lead image:
Page views:
1
From Print Edition:
Highlights: Reported by DNA 7 hours ago.
Lopetegui was dismissed last week after less than five months in charge of Real, following a hefty Clasico defeat by Barcelona and a dire run of form in which they sunk to ninth in La Liga.
The coach has endured a nightmare year after being sacked by Spain on the eve of the World Cup after agreeing to take the Real Madrid job.
However, Carvajal, who won three Champions League titles with Real under Zinedine Zidane, is standing by Lopetegui.
"For me, he's the best coach that I have had," Carvajal told TVE. "Unfortunately, he lacked the bit of luck necessary to continue with us. His way of seeing football, his way of managing the group, of being with the players, is something I share.
"I said it before he arrived at Real Madrid, I'm still saying it now he´s gone, and I will keep saying it until I have a coach that's better than him."
Lopetegui's replacement, interim coach Santiago Solari, has two wins from his two matches in charge, although Carvajal has not featured due to a calf injury.
The right back is not available for Real's trip to the Czech Republic to face Viktoria Plzen in the Champions League on Wednesday.
Article Type:
Report
Sections:
Sports
Agencies:
Reuters
Tags:
Real Madrid
Dani Carvajal
Julen Lopetegui
Football
Barcelona
La Liga
Santiago Solari
Zinedine Zidane
Madrid
Spain
Mon, 5 Nov 2018-07:58pm
Date updated:
Monday, 5 November 2018 - 7:58pm
Article Images:
Reuters
Short URL:
dnai.in/fKzq
Embargo:
Syndicate:
Hide lead image:
Page views:
1
From Print Edition:
Highlights: Reported by DNA 7 hours ago.
↧
Jesy Nelson sends Little Mix fans WILD as she flaunts cleavage in risqué Instagram snap: ‘Too hot!’
*Jesy has caused an Instagram meltdown!*
Mandatory Credit: Photo by REX/Shutterstock (9960455fm)
Little Mix, Jesy Nelson
25th MTV Europe Music Awards, Arrivals, Bilbao, Spain - 04 Nov 2018
Just like the rest of her Little Mix bandmates, Jesy Nelson looked absolutely amazing at the MTV EMAs yesterday evening. …Continue reading »
The post Jesy Nelson sends Little Mix fans WILD as she flaunts cleavage in risqué Instagram snap: ‘Too hot!’ appeared first on CelebsNow. Reported by Now 6 hours ago.
Mandatory Credit: Photo by REX/Shutterstock (9960455fm)
Little Mix, Jesy Nelson
25th MTV Europe Music Awards, Arrivals, Bilbao, Spain - 04 Nov 2018
Just like the rest of her Little Mix bandmates, Jesy Nelson looked absolutely amazing at the MTV EMAs yesterday evening. …Continue reading »
The post Jesy Nelson sends Little Mix fans WILD as she flaunts cleavage in risqué Instagram snap: ‘Too hot!’ appeared first on CelebsNow. Reported by Now 6 hours ago.
↧
Lopetegui is the best coach I've ever had - Carvajal
The Spain full-back has been eager to praise his former manager, who was recently axed by Los Blancos after a disappointing run of form.
Reported by Goal.com 6 hours ago.
↧
More Pages to Explore .....
